CONTENTS
7 OVERVIEW
7 Latest key takeaways
9 DISEASE BACKGROUND
9 Definition
9 Prognosis
9 Risk factors
11 Symptoms
11 Diagnosis
12 Patient segmentation
14 TREATMENT
14 Referral patterns
14 Newly diagnosed Stage I
14 Newly diagnosed Stage II or Stage III
14 Newly diagnosed Stage IV
14 Pharmacological treatment: first-line
15 Pharmacological treatment: recurrent/relapsed disease
17 EPIDEMIOLOGY
17 Incidence methodology
20 MARKETED DRUGS
25 PIPELINE DRUGS
40 KEY REGULATORY EVENTS
40 Early Access To Takeda’s Zejula
40 Lynparza EU Recommendation In Advanced Ovarian Cancer
40 Lynparza Expands In First-Line Ovarian Cancer Maintenance
40 GSK’s Zejula Wins First-Line Ovarian Cancer Use
42 PROBABILITY OF SUCCESS
43 LICENSING AND ASSET ACQUISITION DEALS
43 Epsilogen Licenses Potential Ovarian Cancer Antibody From King’s College London
44 CLINICAL TRIAL LANDSCAPE
45 Sponsors by status
46 Sponsors by phase
47 Recent events
49 DRUG ASSESSMENT MODEL
52 MARKET DYNAMICS
53 FUTURE TRENDS
53 Launches of new targeted therapies and label expansions will drive growth in the ovarian cancer market over the forecast period
53 Biomarker status will become increasingly important in treatment decisions
53 PARP inhibitors will remain the leading drug class within ovarian cancer
54 Competition will be fierce between PD-1/PD-L1 inhibitors in the first-line and first-line maintenance settings
55 CONSENSUS FORECASTS
57 RECENT EVENTS AND ANALYST OPINION
57 Tecentriq for Ovarian Cancer (September 21, 2020)
58 Olvi-Vec for Ovarian Cancer (September 10, 2020)
60 Multiple Drugs for Ovarian Cancer (July 12, 2020)
62 Zejula for Ovarian Cancer (May 31, 2020)
63 Lynparza for Ovarian Cancer (May 29, 2020)
64 Mirvetuximab Soravtansine for Ovarian Cancer (May 29, 2020)
66 Multiple Drugs for Ovarian Cancer (May 29, 2020)
67 Recentin for Ovarian Cancer (May 29, 2020)
68 Vigil EATC for Ovarian Cancer (May 13, 2020)
70 VB-111 for Ovarian Cancer (March 26, 2020)
71 Multiple Drugs for Ovarian Cancer (March 12, 2020)
72 Acelarin for Ovarian Cancer (March 10, 2020)
74 DPX-Survivac for Ovarian Cancer (February 25, 2020)
76 Farletuzumab for Ovarian Cancer (January 31, 2020)
77 Pegilodecakin for Ovarian Cancer (January 30, 2020)
77 Opdivo for Ovarian Cancer (January 24, 2020)
79 AVB-500 for Ovarian Cancer (November 20, 2019)
81 KEY UPCOMING EVENTS
82 KEY OPINION LEADER INSIGHTS
83 UNMET NEEDS
83 Treating platinum-resistant/refractory ovarian cancer
83 Improved testing for earlier detection
84 BIBLIOGRAPHY
85 Prescription information
87 APPENDIX
LIST OF FIGURES
19 Figure 1: Trends in incident cases of ovarian cancer, 2018–27
25 Figure 2: Overview of pipeline drugs for ovarian cancer in the US
25 Figure 3: Pipeline drugs for ovarian cancer, by company
26 Figure 4: Pipeline drugs for ovarian cancer, by drug type
26 Figure 5: Pipeline drugs for ovarian cancer, by classification
42 Figure 6: Probability of success in the ovarian cancer pipeline
44 Figure 7: Clinical trials in ovarian cancer
44 Figure 8: Top 10 drugs for clinical trials in ovarian cancer
45 Figure 9: Top 10 companies for clinical trials in ovarian cancer
45 Figure 10: Trial locations in ovarian cancer
46 Figure 11: Ovarian cancer trials status
47 Figure 12: Ovarian cancer trials sponsors, by phase
49 Figure 13: Datamonitor Healthcare’s drug assessment summary for ovarian cancer
52 Figure 14: Market dynamics in ovarian cancer
53 Figure 15: Future trends in ovarian cancer
58 Figure 16: Tecentriq for Ovarian Cancer (September 21, 2020): Phase III – IMagyn050 (w/Avastin, Newly-Diagnosed)
60 Figure 17: Olvi-Vec for Ovarian Cancer (September 10, 2020): Phase Ib/II – VIRO-15
62 Figure 18: Tecentriq and Avastin for Ovarian Cancer (July 12, 2020)
64 Figure 19: Lynparza for Ovarian Cancer (May 29, 2020): Phase III – SOLO 2 (BRCA Mutation; Relapsed)
66 Figure 20: Mirvetuximab Soravtansine for Ovarian Cancer (May 29, 2020): Phase Ib/II – FORWARD II
67 Figure 21: Lynparza and Recentin for Ovarian Cancer (May 29, 2020)
70 Figure 22: Vigil EATC for Ovarian Cancer (May 13, 2020): Phase II – w/Tecentriq
72 Figure 23: Lynparza and Recentin for Ovarian Cancer (March 12, 2020)
74 Figure 24: Acelarin for Ovarian Cancer (March 10, 2020): Phase II – PRO105
76 Figure 25: DPX-Survivac for Ovarian Cancer (February 25, 2020): Phase Ib/II – DeCidE1
79 Figure 26: Opdivo for Ovarian Cancer (January 24, 2020): Phase III – ONO-4538-23
81 Figure 27: Key upcoming events in ovarian cancer (Figure 1 of 2)
81 Figure 28: Key upcoming events in ovarian cancer (Figure 2 of 2)
LIST OF TABLES
13 Table 1: Patient segmentation, by FIGO stage
18 Table 2: Incident cases of ovarian cancer, 2018–27
21 Table 3: Marketed drugs for ovarian cancer
27 Table 4: Pipeline drugs for ovarian cancer in the US
55 Table 5: Historical global sales, by drug ($m), 2015–19
56 Table 6: Forecasted global sales, by drug ($m), 2020–24
57 Table 7: Tecentriq for Ovarian Cancer (September 21, 2020)
59 Table 8: Olvi-Vec for Ovarian Cancer (September 10, 2020)
61 Table 9: Multiple Drugs for Ovarian Cancer (July 12, 2020)
62 Table 10: Zejula for Ovarian Cancer (May 31, 2020)
63 Table 11: Lynparza for Ovarian Cancer (May 29, 2020)
65 Table 12: Mirvetuximab Soravtansine for Ovarian Cancer (May 29, 2020)
66 Table 13: Multiple Drugs for Ovarian Cancer (May 29, 2020)
68 Table 14: Recentin for Ovarian Cancer (May 29, 2020)
69 Table 15: Vigil EATC for Ovarian Cancer (May 13, 2020)
70 Table 16: VB-111 for Ovarian Cancer (March 26, 2020)
71 Table 17: Multiple Drugs for Ovarian Cancer (March 12, 2020)
73 Table 18: Acelarin for Ovarian Cancer (March 10, 2020)
75 Table 19: DPX-Survivac for Ovarian Cancer (February 25, 2020)
76 Table 20: Farletuzumab for Ovarian Cancer (January 31, 2020)
77 Table 21: Pegilodecakin for Ovarian Cancer (January 30, 2020)
78 Table 22: Opdivo for Ovarian Cancer (January 24, 2020)
79 Table 23: AVB-500 for Ovarian Cancer (November 20, 2019)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!